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Abstract 
Introduction: Lupus erythematosus is a chronic, inflammatory autoimmune disease that can affect multiple organs. Lupus can affect 
many parts of the body, especially in systemic lupus erythematosus (SLE); affected tissues may include the joints, skin, kidneys, heart, 
lungs, blood vessels, and brain. Case report: A 46-year-old female presented with pruritus, photosensitivity and edema of the cheeks of 
about 2 years duration, and was evaluated by a dermatologist. On examination, multiple telangiectasias were present on the cheeks, with 
erythema, edema and a malar rash observed. A review of systems documented breathing difficulty and pleuitic pain, joint pain and joint 
edema,  photosensitivity,  cardiac  dysrhythmia,  and  periodic  pain  in  the  back  close  to  the  kidneys.  Methods:  Skin  biopsies  for 
hematoxylin and eosin testing, as well for direct and indirect immunofluorescence were performed, in addition to multiple diagnostic 
blood tests, chest radiography and directed immunologic testing. Results: The blood testing showed elevated C-reactive protein. Direct 
and indirect immunofluorescence testing utilizing monkey esophagus, mouse and pig heart and kidney, normal human eyelid skin and 
veal brain demonstrated strong reactivity to several components of smooth muscle, nerves, blood vessels, skin basement membrane zone 
and sweat gland ducts and skin meibomian glands. Anti-endomysium antibodies were detected as well as others, especially using FITC 
conjugated  Complement/C1q,  FITC  conjugated  anti-human  immunoglobulin  IgG  and  FITC  conjugated  anti-human  fibrinogen. 
Conclusions:  We  conclude  that  both  direct  and  indirect  immunofluorescence  using  several  substrates  can  unveil  previously 
undocumented autoantibodies in multiple organs in lupus erythematosus, and that these findings could be utilized to complement existing 
diagnostic testing for this disorder. 
 
Streszczenie 
Wstęp:  Toczeń  rumieniowaty  jest  przewlekłą,  zapalną  chorobą  autoimmunologiczną,  która  moŜe  mieć  wpływ  na  wiele  narządów. 
Choroba moŜe oddziaływać na cały organizm, zwłaszcza toczeń rumieniowaty układowy (SLE) moŜe wpływać na stawy, skórę, nerki, 
serce, płuca, naczynia krwionośne i mózg. Opis przypadku: 46-letnia kobieta ze świądem, nadwraŜliwością i obrzękiem policzków od 
około 2 lata została przebadana przez dermatologa. W badaniu obserwowano obecność teleangiektazji na policzkach, z rumieniem i 
obrzękiem. Stwierdzono ponadto udokumentowane trudności w oddychaniu i ból opłucnej, ból stawów i obrzęk stawów, nadwraŜliwość 
na  światło,  zaburzenia  rytmu  serca,  i  okresowy  ból  pleców  w  okolicy  nerek.  Metody:  Wykonywano  biopsję  skóry  w  barwieniu 
hematoksyliną i eozyną, jak równieŜ bezpośrednią i pośrednią immunofluorescencję, oprócz wielu badań diagnostycznych krwi, RTG 
klatki  piersiowej  i  ukierunkowanych  testów  immunologicznych.  Wyniki:  Badania  krwi  wykazały  podwyŜszony  poziom  białka  C-
reaktywnego.  Bezpośrednia  i  pośrednia  immunofluorescencja  z  wykorzystaniem  przełyku  małpy,  serca  myszy  i  świń  oraz  nerek, 
normalnej ludzkiej skóry powiek i cielęcego mózgu wykazały silną reaktywność kilku komponentów mięśni gładkich, nerwów, naczyń 
krwionośnych, zony warstwy podstawnej skóry i błony przewodów gruczołów potowych skóry oraz gruczołów tarczkowych. Wykryto 
przeciwciało przeciwko endomysium, a takŜe inne, zwłaszcza za pomocą sprzęŜonego z FITC Complement/C1q, sprzęŜoną z FITC anty-
ludzką immunoglobulinę IgG, skoniugowaną z FITC oraz anty-ludzki fibrynogen. Wnioski: MoŜemy stwierdzić, Ŝe bezpośrednia i 
pośrednia immunofluorescencja przy uŜyciu kilku substratów moŜe ujawnić wcześniej nieudokumentowane autoprzeciwciała w wielu 
organach w przebiegu tocznia rumieniowatego układowego, oraz Ŝe te wyniki mogą być wykorzystane do uzupełnienia istniejących 
badań diagnostycznych w tym zaburzeniu. 
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Abbreviations:  Systemic  lupus  erythematosus  (SLE),  antinuclear  antibodies  (ANA),  subacute  cutaneous  LE  (SCLE), 
basement  membrane  zone  (BMZ),  chronic  discoid  LE  (DLE),  direct  immunofluorescence  (DIF),  indirect 
immunofluorescence (IIF), 4',6-diamidino-2-phenylindole (DAPI), American College of Rheumatology Criteria (ACRC). 
 
 
Introduction 
Systemic  lupus  erythematosus  (SLE)  is  a 
chronic,  potentially  fatal  autoimmune  disease 
characterized  by  immune  dysregulation;  the 
dysregulation  results  in  the  production  of  antinuclear 
antibodies  (ANAs),  generation  of  circulating  immune 
complexes,  and  activation  of  the  complement  system. 
The disease often manifests unpredictable exacerbations 
and remissions, and unpredictable clinical manifestations 
[1-5]. In SLE, there is an elevated probability for clinical 
involvement  of  the  joints,  kidney,  brain,  lung,  heart, 
serosa  and  gastrointestinal  tract  [1-5].  Women  and 
minorities are disproportionately affected; SLE is most 
common in women of child-bearing age, although it has 
been  reported  in  extremes  of  life  (e.g.,  in  infants  and 
through the tenth decade of life) [1-5].  The prevalence 
of  lupus  erythematosus  in  the  United  States  has  been 
estimated  from  approximately  250,000  patients  to  as 
high  as  2,000,000.  The  pathologic  hallmark  of  the 
disease  is  recurrent,  widespread,  and  diverse  vascular 
lesions [1-5]. In the 60% of SLE patients who experience 
the onset of their disease between puberty and the fourth 
decade of life, the female to male ratio is 9:1. Lupus is 
three times more frequent in African Americans than in 
American Caucasians [1-5]. The ethnic group at greatest 
risk is African Caribbean blacks. The annual incidence of 
SLE  ranges  from  six  to  30  new  cases  per  100,000 
population in relatively low-risk to high-risk groups [1-
5].  The  American  College  of  Rheumatology  Criteria 
(ACRC)  for  lupus  erythematosus  were  developed  to 
nosologically define patients with this disorder [6]. The 
ACRC represent 11 criteria to establish a diagnosis of 
this disease. A patient must present four or more of the 
criteria to be classified as having lupus. These criteria are 
also utilized to insure the appropriateness of subjects for 
epidemiological  or  research  studies.  Although  many 
patients  do  not  fulfill  the  diagnostic  criteria  at  first 
encounter, many do so when followed over time [6].  
 
Case report 
A 46 year old female visited the dermatologist 
for a two year history of skin tightening with pruritis and 
marked light hypersensitivity, especially on the skin of 
the face. On examination, erythematous, edematous areas 
were present on the cheeks, with multiple telangiectasis 
also  noted.  The  patient’s  C-reactive  protein  value  was 
21.3 mg/l (normal limits to 4.0 mg/l); her white blood 
cell count (WBC) at 9.6 x10^3ul (4.0-10 x10^3ul normal 
value), with basophils at 0.5% (0.1-1.6% normal value), 
eosinophils at 0.7% (0,1-0.6% normal value), neutrophils 
at 6.6% (2.9-6.2% normal value), lymphocytes at 1.6% 
(1.8-8.4% normal values), and monocytes at 0.5% (0.15-
1.3% normal value). Thyroid testing values were within 
normal  limits.  Other  laboratory  tests,  including  total 
peripheral blood protein, albumin, alkaline phosphatase, 
aspartate  aminotransferase,  alanine  aminotransferase, 
and total and direct bilirubin were within normal limits. 
Antinuclear  antibodies  (ANA)  were  positive,  at  1:160 
with a homogeneous pattern (up to 1:80 normal value). 
Anti-cyclic citrullinated peptide antibodies (aCCP) were 
present at 9 EliA U/ml(normal limits: 7-10 EliA U/ml), 
and after 1 month increased to 10 EliA U/ml.  No oral 
ulcers or neurological disorders were documented. Anti-
DNA  antibodies  were  negative;  a  Venereal  Disease 
Research Laboratory test (VDRL) was also negative, and 
kidney  function  was  normal.  On  physical  exam,  a 
sensitive area was present on the back in the area of the 
kidneys.  The  EKG  demonstrated  showed  some cardiac 
dysrhythmia. The patient also related periodic chest pain, 
and  pleuritic  pain  was  detected  on  examination.  Other 
physical examination findings included knee and elbow 
pain,  edema  and  erythema; small  cysts  of  the  left  ulna 
and  of  the  ossa  metacarpi  were  also  detected.  A 
thickening  of  the  pleura  on  one  right  lung  lobe  was 
observed  by  chest  radiography.  Following  workup,  the 
patient  was  diagnosed  with  systemic  lupus 
erythematosus (SLE), and prednisone (5mg per day) was 
prescribed for 2 months plus Niacin™ (200mg daily) and 
Rantydyne™  (300mg  daily).  Following  this  treatment, 
the patient did not show skin lesion improvement. Thus, 
these  medications  were  discontinued  and  topical 
tacrolimus and metronidazole cream was initiated on the 
facial lesions.   
 
Materials and Methods 
A punch biopsy of the skin was performed for 
hematoxylin  and  eosin  (H&E)  analysis,  as  well  as  for 
multicolor direct and indirect immunofluorescence (DIF, 
IIF)  utilizing  multiple  antigen  tissues  as  substrates 
including monkey esophagus, porcine and murine heart 
and  kidney,  human  eyelid  and  others.  The  tests  were 
performed ultilizing previously described techniques and 
antibodies [7-13]. 
 
Results 
Hematoxylin and Eosin staining  
H&E staining displayed histologic features of a 
mild  interface  dermatitis,  including  hydropic 
degeneration  of  the  basal  cell  layer.  An  associated 
superficial, perivascular dermal infiltrate of lymphocytes 
and  histiocytes  was  present;  upper  dermal  edema  and 
perivascular  extravasation  of  erythrocytes  was  also 
observed. The H&E, DIF and IIF results are summarized 
in the Figures 1-3. 
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Figure  1.  a  through  c,  clinical  pictures  demonstrating  erythematous,  edematous  plaques  on  the  cheeks  with  fine 
telangiectasias.  d. DIF demonstrating linear FITC conjugated Complement/C3 deposits along the BMZ of the hair follicle 
(yellow staining; red arrow). e. IIF on monkey esophagus substrate, demonstrating positive staining of the endomysium 
utilizing FITC conjugated anti-human Complement/C1q(green staining; red arrow); the nuclei of the substrate cells are 
counterstained  in  blue  using  DAPI.  f.  Similar  to  e,  but  without  nuclear  counterstaining.  g.  IIF  on  monkey  esophagus 
substrate,  demonstrating  positive  staining  against  smooth  muscle  utilizing  FITC  conjugated  anti-human 
Complement/C1Qq(green  staining;  red  arrow).  h.  IIF  on  monkey  esophagus  substrate,  demonstrating  positiviy  against 
small blood vessels utilizing Alexa Fluor 647 conjugated anti-human IgG(orange staining; red arrows). i. IIF on monkey 
esophagus substrate, demonstrating positivity against larger blood vessels utilizing FITC conjugated anti-human fibrinogen 
(green staining; red arrow) 
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Figure 2. a. IIF on monkey esophagus substrate, demonstrating positivity against a large nerve utilizing FITC conjugated 
anti-human Complement/C1q(green staining; red arrows). b. IIF on monkey esophagus substrate, demonstrating positivity 
against several smooth muscle bundles utilizing FITC conjugated anti-human albumin (green staining; red arrows). Muscle 
cell nuclei are counterstained with DAPI in blue. c. IIF on monkey esophagus substrate, demonstrating linear positivity 
against the BMZ (light green staining; red arrow) using FITC conjugated anti-human Complement/C1q FITC and against 
the endomysium (white arrow). d. IIF on monkey esophagus substrate, displaying positivity against the internal layer of the 
esophagus resembling a pattern of anti-fibrillagrin antibodies, using FITC conjugated anti-human Complement/C3 (green 
staining; red arrows). The nuclei of the cells are counterstained with DAPI(blue staining). e. DIF of skin demonstrating 
positivity against an eccrine sweat gland ductus using FITC conjugated anti-human IgG (red arrow), against the BMZ 
(white arrow), and some intercellular staining in some patches of the epidermal stratum spinosum (blue arrow). Finally, 
note the orange staining against small blood vessels using Alexa Fluor 647 conjugated anti-human IgG(yellow arrows). f. 
Similar to e, but in this case we counterstained the nuclei with Dapi (blue staining). The white arrow shows reactivity 
against the acrosyringium, the yellow arrows against the blood vessels and the red arrow against a sweat gland ductus 
 
 
 
 
Discussion 
  The  precise  etiology  of  SLE  remains 
unidentified.  A  genetic  predisposition,  sex  hormones, 
and  environmental  trigger(s)  likely  result  in  the 
dysregulated  immune  response  that typifies the disease 
[1-5]. A role for genetics and environmental factors is 
suggested  by  the  increased  incidence  of  the  disease  in 
selected families and geographic regions [1-5].  
A clinical cutaneous presentation of lupus erythematosus 
might include some SLE findings with findings of other 
variants, such as chronic discoid or subacute cutaneous 
lupus. However, the most common skin lesions seen in  
SLE are those of the acute type (including a malar rash 
with  photosensitivity  and  telangiectasias),  as 
demonstrated in this case [14-19].  DIF and IIF studies 
on  skin  samples  for  lupus  have  classically  shown 
granular  and/or  linear  deposits  of  IgG,  IgA  and  IgM 
along  the  basement  membrane  zone  of  the  skin,  and 
selected  immunoreactants  present  surrounding  dermal 
blood  vessels  [14-18].  However,  deposits  of 
immunoglobulins  and  complement  have  been  also 
recently documented to dermal sweat glands, sebaceous 
glands and nerves [7,8,10-12]. 
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Figure  3.  a.  IIF  utilizing  veal  brain  shows  immunoreactivity  to  several  vessels  using  FITC  conjugated  anti-human 
fibrinogen (green staining, yellow arrows). The nuclei were counterstained with DAPI(blue). b. IIF utilizing normal human 
skin from an eyelid cosmetic surgery, and utilizing FITC conjugated anti-human Complement/C1q antibodies directed 
against the meibomian glands and their ducts (green staining, red arrows). c. Same tissue and antibody as in b; in this case, 
the  antibodies  recognized  the  modified  sweat glands of the eyelids(green staining; red arrow). d. IIF utilizing murine 
kidney shows immunoreactivity to the capsule of the kidney using FITC conjugated anti-human fibrinogen(green staining; 
red arrow). The nuclei were counterstained with DAPI(blue). e. Similar to d, but in this case the positivity is against renal 
glomeruli(green staining; red arrow). f. IIF using porcine heart demonstrates immunoreactivity to several cardiomyocytes 
using FITC conjugated anti-human-IgG FITC(green staining, red arrow). The nuclei were again counterstained with DAPI 
in blue. g. IIF utilizing porcine instestine demonstrates immunoreactivity to several cells using FITC conjugated anti-
human-IgG FITC(green staining, red arrow). The nuclei were counterstained with DAPI. h. IIF using murine kidney shows 
immunoreactivity to a kidney tubule utilizing FITC conjugated anti-human fibrinogen(green staining, red arrow). i. IIF 
utilizing normal human eyelid skin from cosmetic surgery using FITC conjugated anti-human Complement/C1q antibodies 
directed against epidermal keratinocytes in a perinuclear fashion (green staining). Keratinocyte nuclei are counterstained in 
blue with DAPI 
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The  origin  of  autoantibody  production  in  SLE  is 
uncertain;  suggested  possibilities  have  included  an 
antigen  driven  process,  spontaneous  B-cell  hyper-
responsiveness,  or  impaired  immune  regulation. 
Regardless  of  the  etiology  of  autoantibody  production, 
SLE is associated with impaired clearance of circulating 
immune  complexes  [1-5].    More  is  known  about  the 
pathogenic  cellular  and  molecular  events  which  are 
responsible  for  the  vascular  lesions  in  SLE  than 
regarding the precise origins of the autoimmunity [1-5]. 
Disease  manifestations  result  from  recurrent  vascular 
injury  due  to  immune  complex  deposition, 
leukothrombosis,  or  thrombosis  [1-5].  Additionally, 
cytotoxic antibodies can mediate autoimmune hemolytic 
anemia  and  thrombocytopenia,  while  antibodies  to 
specific  cellular  antigens  can  disrupt  cellular  function. 
An example of the latter is the association between anti-
neuronal antibodies and neuropsychiatric SLE [1-5]. In 
our study, our DIF and IIF results and the patient review 
of the systems directed us to search for damage in other 
organs,  especially  antibodies  to  smooth  muscle  and 
blood vessels. This patient was found to have pleuritis; 
some authors have also described pleuitic antibodies to 
be present in cases of SLE [20,21].   
Our  findings  are  of  interest,  because  tests  other  than 
classical  antibody  testing  may  be  of  value  in  the 
diagnosis  of  SLE.    Recently,  murine  liver  and  kidney, 
and epithelial cell lines obtained from human laryngeal 
carcinoma  (including  Hep-2)  have  been  explored  as 
substrates for ANA testing. Such ANA testing has high 
diagnostic sensitivity, and most ANAs are of IgG isotype 
[23]. Other autoantibodies routinely tested for lupus and 
anti-cytoplasmic  antibodies  (such  as  anti-Ro/SSA  and 
anti–t-RNA synthetases) are not always readily detected 
on these substrates due to scarcity of the antigen in Hep-
2  cells,  and/or  antigen  leaching  and  denaturation 
secondary to fixation procedures [23]. At present, of the 
approximately  40  types  of  possible  diagnostic 
fluoroscopic  patterns  identified  in  one  pertinent  study, 
only 19 are directly associated with clinical diagnoses; 
moreover,  for  many  autoantibodies,  the  target 
autoantigen has not been identified with certainty [23].  
We  thus  conclude  that  there  are  several  patterns  of 
autoantibodies  that  have  not  been  well  elucidated,  and 
could assist in the laboratory diagnosis of SLE. 
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